Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhGH + rhIGF-1 combination therapy dose-selection trial in children with short stature and IGF-1 deficiency
2019-000843-29Phase 2
- Sponsor
- Ipsen
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of somatropin and mecasermin in Idiopathic Short Stature (ISS) and insulin-like growth factor 1 deficiency (4 arms), sponsored by Ipsen. Primary endpoint: Height velocity during the first year of treatment.
02
Drugs
somatropinmecasermin
03
Conditions
Idiopathic Short Stature (ISS)insulin-like growth factor 1 deficiency
Beyond the preview
Go deeper on 2019-000843-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000843-29.